Cure Genetics
Next-generation cell and gene therapies for solid tumors and genetic disease
Suzhou, China · Founded 2016 · $77.0M raised
- Headquarters
- Suzhou
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Website
- curegenetics.com
- Total Funding
- $77.0M
- Last Round
- $60.0M Series BJan 2022
- Rounds
- 2
About
Cure Genetics (克睿基因) is a clinical-stage biotechnology company founded in 2016 and headquartered in Suzhou, China, developing next-generation cell and gene therapies for solid tumors and genetic diseases using two proprietary technology platforms. Its AIMS CAR-NKT platform engineers natural killer T cells for superior tumor microenvironment penetration and anti-tumor activity, demonstrated in the first human trial of CAR-NKT therapy for renal cell carcinoma (CGC729). Its VELP AAV platform enables discovery of novel adeno-associated virus serotypes with organ-specific targeting for liver, neurological, cardiac, and kidney diseases, powering a major collaboration with Boehringer Ingelheim.
Summary
Cure Genetics is a Biotech company based in Suzhou, China, founded in 2016. It has raised $77.0M in total across 2 rounds, most recently a $60.0M Series B round in Jan 2022. Investors include Advantech Capital and Qiming VP.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2022
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Global contract research organization providing comprehensive drug development and laboratory ser...